IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04836182
- Locations
- 🇵🇱
Indywidualna Specjalistyczna Praktyka Lekarska, Lodz, Poland
🇭🇺Semmelweis Egyetem - Varosmajori Sziv es Ergyogyaszati Klinika, Budapest, Hungary
🇺🇸Arkansas Cardiology, Little Rock, Arkansas, United States
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT04768972
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04731623
- Locations
- 🇨🇦
BioPharma Services, Inc., Toronto, Ontario, Canada
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT04714320
- Locations
- 🇺🇸
Nature Coast Clinical Research - Crystal River, Crystal River, Florida, United States
🇺🇸Eagle Clinical Research, Chicago, Illinois, United States
🇺🇸Holston Medical Group, Kingsport, Tennessee, United States
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04659096
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- Familial Chylomicronemia Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT04568434
- Locations
- 🇵🇹
Hospital da Senhora da Oliveira - Guimaraes, Creixomil, Portugal
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇳🇴The Lipid Clinic (Oslo University Hospital), Oslo, Norway
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
- Conditions
- Acromegaly
- Interventions
- Drug: GHR-LRX
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04522180
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇱🇹Vaidoto Urbanaviciaus Individuali imone, Alytus, Lithuania
🇮🇹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)
- Conditions
- Chronic BronchitisChronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04441788
- Locations
- 🇩🇪
MECS Research GmbH, Berlin, Germany
🇩🇪Pneumologisches Studienzentrum Markgrafenstrasse, Berlin, Germany
🇩🇪Hamburger Institut far Therapieforschung GmbH, Hamburg, Germany
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaRelapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04398485
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04307381
- Locations
- 🇳🇱
Ionis Investigative Site, Amsterdam, Netherlands